Benchmark sees long-term growth in aquaculture

0
32
  • Benchmark receives authorisation in Norway for salmon treatment
  • Benchmark Holdings ‘significant moment’ passing last regulatory step for salmon treatment approval
salmon

Quick facts: Benchmark Holdings PLC

Follow

View company profile

Benchmark’s mission is to enable aquaculture producers to improve their sustainability and profitability. We bring together biology and technology, to develop innovative products which improve yield, quality and animal health and welfare for our customers. We do this by improving the genetic make-up, health and nutrition of their stock – from broodstock and hatchery through to nursery and grow out. Benchmark has a broad portfolio of products and solutions, including salmon eggs, live feed (Artemia), diets and probiotics and sea lice treatments.

02 Jul 2021

() said it had received marketing authorisation from the Norwegian Medicines Agency (NoMA) for EctosanVet (BMK08), its pioneering treatment for sea lice in salmon.

Sea lice are one of the biggest biological challenges in salmon farming, said Benchmark, and estimated to cost producers more than US$1bn annually, and US$600mln in Norway alone.

Ectosan Vet will be the first sea lice veterinary medicinal treatment to be introduced to the Norwegian salmon market in over a decade, it added.

The final steps for commercialisation are the ratification of the MRL (Maximum Residue Limit) into Norwegian regulation and the approval of product labels by the NoMA.

Read more

18 May 2021

(), the aquaculture biotechnology company, saw growth in revenues and earnings in the six months to the end of March.

Revenue from continuing operations rose to GBP59.5mln from GBP56.2mln in the corresponding period a year earlier. Had exchange rates stayed the same from a year earlier, revenue would have been up 11% year-on-year at GBP62.3mln.

Read more

16 Apr 2021

() said that the MRL (Maximum Residue Limit) for its novel sea lice treatment BMK08 has been ratified under European Law.

The MRL confirms the safety of Benchmark’s sea lice solution for consumers and represents a significant milestone in the regulatory approval process towards the anticipated commercial launch of BMK08 and CleanTreat in Norway, said the statement.

Read more

16 Jul 2021

‘s () Trond Williksen and Septima Maguire join Proactive London after receiving marketing authorisation from the Norwegian Medicines Agency (NoMA) for its pioneering treatment for sea lice in salmon.

EctosanVet (BMK08) treats one of the biggest biological challenges in salmon farming – sea lice. This problem comes at an estimated cost to producers of more than US$1bn annually, and US$600mln in Norway alone.

Ectosan Vet will be the first sea lice veterinary medicinal treatment to be introduced to the Norwegian salmon market in over a decade.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…

FOR OUR FULL DISCLAIMER CLICK HERE

Benchmark Holdings ‘significant moment’ passing last regulatory step for…

Benchmark Holdings PLC’s (LON:BMK) Trond Williksen and Septima Maguire join Proactive London after receiving marketing authorisation from the Norwegian Medicines Agency (NoMA) for its pioneering treatment for sea lice in salmon.

EctosanVet (BMK08) treats one of the biggest biological…

15 hours, 30 minutes ago

3 min read

LEAVE A REPLY

Please enter your comment!
Please enter your name here